Search - tctmd.com

Displaying 1 - 20 of 26

Sort: Relevancy | Date

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Todd Neale

December 10, 2019

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Daily News

Lipid Levels Declining in US, With Drops Seen After 2013 Guideline Release

Michael O'Riordan

November 11, 2019

News Daily News

Obesity Prevalence Triples in China Over 10-Year Span

Michael O'Riordan

October 28, 2019

News Daily News

New Review Questions Statin Benefit in Lower-Risk Primary Prevention Patients

Michael O'Riordan

October 22, 2019

News Daily News

Disparate US Trends in Early CVD Deaths Speak to Need for Targeted Prevention

Caitlin E. Cox

October 21, 2019

News Daily News

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

L.A. McKeown

October 21, 2019

News Conference News ESC 2019

New PURE Insights: CVD Deaths Dip in Rich Nations Amid Risk-Factor Surprises

Michael O'Riordan

September 04, 2019

News Conference News ESC 2019

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

Shelley Wood

September 01, 2019

News Conference News ESC 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Michael O'Riordan

September 01, 2019

News Daily News

Decline in US Deaths From CVD and Diabetes Is Leveling Off

Todd Neale

August 27, 2019

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Daily News

Genes Bolster Case for Link Between Insomnia and CV Risk

Alison Palkhivala

August 19, 2019

News Conference News EAS 2019

CHD Mortality Significantly Elevated in Patients With Severe FH

Michael O'Riordan

May 29, 2019

News Daily News

FDA Tallies Cases of Fournier Gangrene in Patients Taking SGLT2 Inhibitors

Michael O'Riordan

May 08, 2019

News Daily News

Mortality From Heart Failure Increasing in United States

Michael O'Riordan

May 06, 2019

News Daily News

Younger Type 2 Diabetes Patients Face Higher Mortality and CVD Risks

Michael O'Riordan

April 10, 2019

News Daily News

Many Statin-Eligible Patients Don’t Take Meds, and Say Doctor Is to Blame

Michael O'Riordan

March 27, 2019

News Conference News ACC 2019

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

Shelley Wood

March 26, 2019

News Conference News ACC 2019

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Michael O'Riordan

March 20, 2019

Advertisement

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Lipid Levels Declining in US, With Drops Seen After 2013 Guideline Release

Obesity Prevalence Triples in China Over 10-Year Span

New Review Questions Statin Benefit in Lower-Risk Primary Prevention Patients

Disparate US Trends in Early CVD Deaths Speak to Need for Targeted Prevention

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

New PURE Insights: CVD Deaths Dip in Rich Nations Amid Risk-Factor Surprises

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Decline in US Deaths From CVD and Diabetes Is Leveling Off

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Genes Bolster Case for Link Between Insomnia and CV Risk

CHD Mortality Significantly Elevated in Patients With Severe FH

FDA Tallies Cases of Fournier Gangrene in Patients Taking SGLT2 Inhibitors

Mortality From Heart Failure Increasing in United States

Younger Type 2 Diabetes Patients Face Higher Mortality and CVD Risks

Many Statin-Eligible Patients Don’t Take Meds, and Say Doctor Is to Blame

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content